+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Lymphokine activated killer cells potential role as a purging agent for autologous bone marrow transplantation



Lymphokine activated killer cells potential role as a purging agent for autologous bone marrow transplantation



Clinical Research 36(3): 410A




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 028657395

Download citation: RISBibTeXText


Related references

Autologous bone marrow purging by lymphokine-activated killer cells: rationale and prospects. Pathology and Immunopathology Research 7(6): 477-482, 1988

Purging of tumor contaminated human bone marrow utilizing autologous lymphokine activated killer cells. Clinical Research 35(3): 523A, 1987

Lymphokine-activated killer cell purging of leukemia cells from bone marrow prior to syngeneic transplantation. Transplantation 46(3): 433-438, 1988

In vitro LAK (lymphokine activated killer) activity following autologous peripheral blood stem cell is significantly greater than that following autologous bone marrow and allogeneic bone marrow transplantation. Bone Marrow Transplantation 16(2): 277-281, 1995

Lymphokine-activated killer cells in autologous bone marrow transplantation. Evidence against inhibition of engraftment in vivo. Transplantation 54(6): 1008-1013, 1992

Generation of lymphokine-activated killer (LAK) cells and possible implications in autologous bone marrow transplantation--a preliminary report. Proceedings of the National Science Council, Republic of China. Part B, Life Sciences 14(1): 47-53, 1990

Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplantation 12(2): 159-163, 1993

Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplantation 16(2): 283-288, 1995

Consolidative immunotherapy with IL-2 with or without lymphokine activated killer cells after autologous bone marrow transplantation for acute myelogenous leukemia and malignant lymphoma. Journal of Cellular Biochemistry Supplement 0(18B): 52, 1994

The sensitivity of leukemic bone marrow to simvastatin is lost at remission: a potential purging agent for autologous bone marrow transplantation. Journal of Investigative Medicine 43(3): 269-274, 1995

Purging of bone marrow contaminated with a myeloid leukemia cell line by interleukin-2 and lymphokine activated killer cells. Proceedings of the American Association for Cancer Research Annual Meeting 34(0): 460, 1993

Lymphokine-activated killer cell lysis of human neuroblastoma cells: a model for purging tumor cells from bone marrow. Clinical Immunology and Immunopathology 46(1): 150-156, 1988

Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies. Cancer Research 49(20): 5509-5513, 1989

Natural killer cells modifications induced by mafosfamide marrow purging for autologous bone marrow transplantation. Experimental Hematology (Charlottesville) 20(6): 818, 1992

Lymphokine-activated killer (LAK) cell purging of bone marrow. Progress in Clinical and Biological Research 333: 125-35; Discussion 136-7, 1990